June 2026 delivered a wave of new clinical data and regulatory updates that clarify the path forward for medical weight management. From the ACP’s new prescribing hierarchy to the launch of the Medicare GLP-1 Bridge and the rising potency of multi-agonists, the need for structured, physician-led care has never been more urgent.
Hair shedding is one of the most commonly reported but least-addressed sequelae of GLP-1-related weight loss, and it often overlaps with menopausal female pattern hair loss in the same patient. Aesthetic providers who can identify both presentations and offer structured interventions have a meaningful clinical and practice expansion opportunity.
May 2026 brought a wave of new clinical data and market shifts that underscore a critical reality: prescribing a GLP-1 is only the beginning of obesity care. From managing the “off-ramp” of weight regain to addressing the complex reality of muscle mass changes, the need for structured, physician-led weight management programs has never been clearer.
If you’ve been considering aesthetic medicine, 2026 may be the best entry window in years — a documented provider shortage, a wave of new patients, and a training path that’s more accessible than most providers realize. Here’s the realistic roadmap.
Patients are arriving at aesthetic and weight management practices asking about NAD+. Here’s the clinical case for IV delivery, what the evidence actually shows, and how to build it into a practice already serving this patient.
63% of patients on GLP-1 medications are new to aesthetics — and they’re arriving with a distinct presentation that requires a different clinical and business approach. Here’s what GLP-1 aesthetic patients actually need from their provider, and how to build a practice model that serves them well.
April 2026 brought a wave of regulatory and clinical developments that GLP-1 providers need to act on before summer. From a landmark FDA compounding proposal to the Medicare GLP-1 Bridge program’s July 1 launch, here is what changed and what it means for your practice.
March 2026 delivered some of the most consequential GLP-1 news of the year — from a sweeping FDA enforcement action against telehealth compounders to the approval of Foundayo, the first oral GLP-1 with no food or water restrictions. Here’s what every provider needs to know this month.
Two oral GLP-1 medications for obesity are now FDA-approved — Eli Lilly’s Foundayo (orforglipron) and Novo Nordisk’s Wegovy pill (semaglutide 25 mg) — and they are meaningfully different. This clinical comparison breaks down the trial data, dosing requirements, and pricing so providers can have informed conversations with patients.
Insurance-based practice has become one of the leading structural drivers of physician burnout — but the solution is not a wellness seminar. For a growing number of physicians, cash-based aesthetic medicine is the deliberate exit strategy that removes the administrative burden and puts them back in control of their time and income.
Terms and conditions apply. Offer expires September 30.